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[57] ABSTRACT 
Spin trapping compositions in general have now been dis 
covered to be e?°ective in treating a variety of disorders, 
including disorders such as those arising from ischemia, 
infection, in?ammation, exposure to radiation or cytotoxic 
compounds, not just of the central and peripheral nervous 
systems but of peripheral organ disease having a wide 
variety of etiologies. In the preferred embodiment, the 
compositions for treating tissue damage from ischernia 
contain PBN, or active derivatives thereof, in a suitable 
pharmaceutical carrier for intravenous, oral, topical, or 
nasal/pulmonary administration. Many different disorders 
can be treated using these compounds, including diseases or 
disorders of the central and peripheral nervous systems, and 
disorders arising from ischemia, infection, in?ammation, 
oxidation from exposure to radiation or cytotoxic com 
pounds, as well as due to naturally occurring processes such 
as aging. 
36 Claims, No Drawings 
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SPlN TRAPPING PHARMACEUTICAL 
COMPOSITIONS AND METHODS FOR USE 
TI-HEREOF 
This is a continuation of application Ser. No, 08/052,870 
?led on Apr. 26, 1993, (now abandoned) which is a CONT 
of Ser. No. 07/716,952, ?led Jun. 18, 1991, (now aban 
doned) which is a CIP of Ser. No. 07/589,177, ?led Sep. 27, 
1990, (now abandoned) which is a CIP of Ser. No. 07/422, 
651, ?led Oct. 17, 1989, now U.S. Pat. 5,025,032. 
BACKGROUND OF THE INVENTION 
The present invention is a method and compositions 
containing spin trapping agents for the treatment of dys 
functions and disease conditions arising from oxidative 
damage. 
As ?rst described in U.S. Pat. Ser. No. 07/422,651 (U.S. 
Pat. No. 5,025,032), oxygenated tissue suffers damage, in 
many cases permanent damage, if it becomes ischemic and 
is then reperfused. Brain appears to be uniquely susceptible 
to ischernia/reperfusion injury. Certain areas of the brain, for 
example, the hippocampus and spinal cord, are more sus~ 
ceptible than other regions of the brain. As a result, 
ischemia/reperfusion injury to brain may have a multiplica 
tive e?°ect simply because of the necessity for complete 
integrity of all regions in order to have proper functioning. 
Free radicals have been postulated to be mediators of 
reperfusion damage. The important production sites of such 
radicals as the superoxide (.O"2) and hydroxyl (OH——) 
species are the mitochondrial respiratory chain and the 
sequences catalyzed by cyclooxygenase and lipoxygenase. 
However, radicals are also formed during autoxidation of 
many compounds (e.g., catecholarnines). Several ischemic 
events favor a spurt of free-radical formation, such as those 
causing oxidation of polyenoic free fatty acids, release and 
reuptake of catecholamines, and oxidation of hypoxanthine 
by xanthine oxidase. Despite these events occurring during 
recirculation, when the O2 supply is restored, they represent 
metabolic cascades triggered by agonist-receptor interac 
tions, energy failure, and/or calcium in?ux during the insult. 
Although free radical formation was‘postulated to be a 
likely cause of ischemic damage, it was di?icult to directly 
demonstrate that such formation occurs and/or that it was 
su?iciently pronounced to overwhelm the antioxidative 
defense of the tissue, as reviewed by Curran, et al., Mol. 
Cell. Biol. 5, 167-172 (1985). Phenyl butyl nitrone (PBN) 
has been used in a number of these in vitro research studies 
using spin trapping to look for free radicals, but until 
demonstrated by the data in U.S. Ser. No. 07/422,651, (U.S. 
Pat. No. 5,025,032) there has been no data to support the 
proposition that it could be useful in vivo, particularly with 
respect to treatment of tissue damage in the central nervous 
system. In vivo, the drug must be able to both cross the blood 
brain barrier and act in a manner which reduces tissue 
damage during or following ischemia. 
In U.S. Ser. No. 07/589,177, (now abandoned) the use of 
PBN and related compounds, as well as 5,5-dimethyl pyr 
roline N-oxide (DMPO) and ot-(4-pyridy1-1~oxide)-N-tert 
butylnitrone (POBN), for treatment of aging was described. 
Age related changes in central nervous system function have 
generally been associated with the loss of cells, a widening 
of lateral ventricles and de?cits in short term memory. The 
precise mechanisms of functional changes as a result of 
aging, or other diseases associated with aging, have not 
generally been agreed upon, including several mechanisms 
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for the generation of oxidized material in the brain. A 
marked reduction in certain neurotransmitter receptor sys 
tems has been associated with increased oxidation of pro— 
teins. For example, decreases in muscarinic receptors and 
other cholinergic systems have been characterized as they 
relate to alterations in functions in Alzheimers disease. It has 
also been hypothesized that aging is associated with multiple 
minor periods of ischemia (multi-infarct conditions or tran~ 
sient ischemia attacks) which, over a period of time, may 
give rise to the production of oxidized protein. 
The demonstration in a variety of systems, both neural 
and nonneural, that there is an age related enhancement of 
the level of oxidized protein in tissue gives rise to the 
possibility that age related dysfunctions in the central ner 
vous system may be associated with the build-up of oxidized 
proteins and oxidized macromolecules within neurons 
throughout the central nervous system. The hypothesis is 
that cells which have a buildup of oxidized protein are less 
functional and less able to maintain the speci?ed role of 
those cells in that particular area of the central nervous 
system. The data presented in U.S. Ser. No. 07/589,177 (now 
abandoned) was the ?rst report of substantial investigations 
in which alterations in the oxidized protein burden of the 
central nervous system was manipulated and correlated with 
a functional outcome on the part of the animal. 
There are a number of other disorders and diseases which 
have now been postulated to be associated with oxidation of 
proteins, including many central nervous system (CNS) 
diseases besides stroke and aging, including Parkinsonism, 
trauma, vascular headaches, and neuroanesthesia adjunct, as 
well as peripheral nervous system diseases such as diabetic 
peripheral neuropathy and traumatic nerve damage, as well 
as peripheral organ diseases. Examples of peripheral organ 
diseases include atherosclerosis, pulmonary ?brosis, pancre‘ 
atitis, angioplasty, multiple organ failure, burns, and 
ischemic bowel disease. 
It is therefore an object of the present invention to provide 
spin-trapping composition and methods for use thereof 
which are useful in preventing or reversing ischemic damage 
in vivo, in the (CNS, resulting from diseases such as stroke, 
aging, Parkinsonism, concussion, Berry aneurysm, ventricu 
lar hemorrhage and associated vasospasm, ‘spinal cord 
trauma, vascular headaches, and neuroanesthesia adjunct. 
It is another object of the present invention to provide 
spin-trapping compositions, and methods for use thereof, 
which are useful in treating damage in vivo resulting from 
peripheral nervous system diseases, including diabetic, 
peripheral neuropathy and traumatic nerve damage. 
It is still another object of the present invention to provide 
spin-trapping compositions, and methods for use thereof, 
which are useful in preventing or reversing free radical 
damage in vivo resulting from injury, infection and in?am 
mation, especially peripheral organ diseases such as chronic 
obstructive pulmonary disease (COPD), atherosclerosis 
(both diabetic and spontaneous), pulmonary ?brosis due to 
anti-cancer, pancreatitis, angioplasty, multi-organ failure 
following trauma, burns, and ischemic bowel disease. 
It is a further object of the present invention to treat 
disorders not associated with oxidation, :such as undesirable 
HDL/LDL ratios, as well as the treatment of damage‘arising 
from exposure to cytotoxic compounds and radiation. 
SUMMARY OF THE INVENTION 
Spin trapping compositions in general have now been 
discovered to be effective in treating a variety of disorders, 
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including disorders such as those arising from ischemia, 
infection, in?ammation, exposure to radiation or cytotoxic 
compounds, not just of the central and peripheral nervous 
systems but of peripheral organ disease having a wide 
variety of etiologies. In the preferred embodiment, the 
compositions for treating tissue damage from ischernia 
contain PBN, or active derivatives thereof, having the fol~ 
lowing general formula, in a suitable pharmaceutical carrier 
for intravenous, oral, topical, or nasal/pulmonary adminis 
tration. ’ 
H O“ 
\ / 
C:N+ 
/ 
X Y 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
0 
ll 
Z—C—, 
or Z; or 
O 
—CH=N 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
Other preferred spin-trapping agents include 5,5-dimethyl 
pyrroline N-oxide (DMPO), ot-(4-pyridyl l-oxide)-N-tert 
butylnitrone (POBN), and (TEMPO) and spin-trapping 
derivatives thereof. Examples of useful derivatives of PBN 
include imidazole PBN, phenothiazinyl PBN, nitrosoben 
zene PBN, 2 methyl-nitrosopropane PBN, halogenated 
derivatives, bifunctional derivatives, conjugates, dimers and 
cyclodextran polymers of PBN. Conjugates of calcium 
channel blockers such as nimodipine, nicardipine, nife 
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dipine, nitrendipine, diltrazam, and ?unarazine, digitalis, 
propranalol, desferal, and lazaroids, antiin?ammatories such 
as prednisone, antioxidants such as vitamin E, and neuro 
active compounds such as L-DOPA and acetaminophen are 
possible, although in some cases spacers will be required 
between the spin-trap and the conjugated compound in order 
to preserve maximum activity. The essential criteria for the 
selection of the spin trap is that it actively trap free radicals 
without cytotoxicity, and that in the applications where 
access to the CNS is required for e?icacy, that the com 
pounds pass through the blood brain barrier. 
Many diiferent disorders can be treated using these com 
pounds, including diseases or disorders of the central and 
peripheral nervous systems, and disorders arising from 
ischemia, infection, in?ammation, oxidation from exposure 
to radiation or cytotoxic compounds, as well as due to 
naturally occurring processes such as aging. 
4 
DETAILED DESCRIPTION OF THE 
INVENTION 
it has now been discovered that, further to the methods 
using PBN, DMPO, and POBN, and their derivatives for the 
treatment and prevention of ischemic damage described and 
claimed in U.S. Ser. No. 07/422,651 ?led Oct. 17, 1989 
(now U.S. Pat. No. 5,025,032) and U.S. Ser. No. 07/589,177 
?led Sep. 27, 1990, (now abandoned) the teachings of which 
are speci?cally incorporated herein, spin-trapping agents are 
generally useful in preventing or treating symptoms associ 
ated with a very wide range of disorders of the central and 
peripheral nervous system, as well as peripheral organ 
disfunction and disease, including not just aging, trauma, 
ischemia, but disorders as disparate as undesirable ratios of 
lipoproteins, ulcerative colitis, and damage arising from 
exposure to radiation and cytotoxic compounds (chemo 
therapeutic compounds, in most instances). 
As used herein, a free radical scavenger or spin-trap 
reagent is a molecule that will form a stable complex with 
a free radical. A free radical carbon trap is a molecule in 
which the free radical is localized on a carbon atom or a 
nitrogen atom. As a result of this chemical bond formation, 
the free radical is no longer damaging to the cell. 
Useful Spin-T rapping Compounds 
POBN and Derivatives Thereof 
The preferred spin-trapping compounds are phenyl 
N-tert-butylnitrone, also referred to as ot-phenyl t-butyl 
nitrone (PBN), and derivatives thereof. PBN is the most 
preferred compound at this time, having no measurable 
effect on normal or uninjured cells, although a number of 
derivatives are also useful, including hydroxy derivatives, 
especially 2-, 3- or 4-hydroxy PBN and mono-, di- and 
trihydroxy tert-butyl nitrone; esters, especially esters which 
release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such as the 
acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl 
nitrone, such as the ethyl derivative, or phenyl hydroxybutyl 
nitrone, such as the acetoxy derivative; alkoxyl derivatives, 
especially alkoxyl derivatives which release 2-, or 4-hydrox 
yphenyl t-butyl nitrone, such as the methyl derivative; and 
acetarnide derivatives, especially acetarnide derivatives 
which release 2-, or 4 arninophenyl t-butyl nitrone, such as 
the acetyl derivative; diphenyl nitrone (PPN) and the analo 
gous diphenyl nitrone derivatives. As used herein, “PBN” 
refers to both phenyl N-tert-butyl nitrone and derivatives 
thereof, unless otherwise stated. 
5,622,994 
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The general formula for PBN and useful derivatives and n is a whole integer from 1 to 5; or 
thereof is: 0 
11 
H 0- NH-C-Z; 
\ / s 
C=N+ 
/ 
X Y 
Y is a tert»buty1 group that can be hydroxylated or 
wherein? acetylated on one or more positions; phenyl; or 
X is phenyl or OW 
(OR)n ; 
15 
wherein W is 
whereln R is H, - O O O 
0 II II II 
[I 20 C—-CH3, NH—C—Z, C—OZ, 
Z—C— 
or Z; or 
—CH=N are: 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
25 The formulas for PBN and speci?c derivatives thereof 
PBN 
DERIVATIVES OF PBN 
l 
_(|:_ NO 0 
O-N 1 O 
\\ C==N + c c 
c 
PBN + NTI‘ROSOBENZENE 
0 PBN PEN 
\/ PBN 
O < 
. ' PBN 
‘R PBN PE |_ 
/\ /\ PBN 
PBN PBN 
PBN CYCLODEXTRAN POLYMER 
5,622,994 
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PBN CYCLIZED 
PBN DERIVATIVES 
R3 
WHEREIN R = HALOGEN, METHYL, OR METHOXY 
Other spin-trapping agents can also be used, such as 55 by US. Pat. No. 4,224,340 to Campbell, et al., the teachings 
5,5-dimethyl pyrroline N-oxide (DMPO), ot-(4-pyridyl of which are incorporated herein. 
1-oxide)-N-tert-butylnitrone (POBN), N-tert-butyl-ot-(4-ni- DMPO and Derivativ?s Thereof 
tro-phenyl)nitrone, N-tert-butylot-(2-sulfophenyl)nitrone, The general formula for DMPO’ and Speci?c derivatives 
3,3,5,5-tetramethyl-l-pyrroline N-oxide, and 2,4,6-tri-tert- 60 are: 
butylnitrosobenzene (BNB), and spin-trapping derivatives 
thereof. Derivatives are made using standard techniques, for D 
. . A / example, by subst1tut1on of the methyl groups, for example, N 
with halogens or sulfur. Many compounds are commercially B \l/ 
available or can be synthesized using methods known to 65 0 
those skilled in the art. q-phenyl-N-phenylnitrone com 
pounds for use as topical antiin?ammaton'es are described 
5,622,994 
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wherein A and B are independently CH3, CH2 OH, 
CHZOW, or 
(CW)! 
11 is an integer from 1 to 5 
wherein W is 
or Z; and 
Z is a C1 to C 5 straight or branched alkyl group. 
DMPO dimer 
C C O 
DMPO conjugated to TEMPO 
0 
PBN conjugated to DMPO 
POBN and Derivatives Thereof 
The general formula for POBN is: 
O 
0%2 
wherein 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
10 
35 
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OW 
wherein W is —C—CH3, 
or Z; and 
S=H, (OR),,, wherein R is H, 
Y 
n is a whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group. 
TEMPO and Derivatives Thereof 
2,2,6,6-tetramethyl piperidinooxy (TEMPO) is a nitrox 
ide organic free radical trap. The synthesis and chemistry of 
nitroxide free radicals is referenced by Galfney, B. J., pp. 
l84~238 in Spin Labeling in Pharmacology Berliner, L.v H., 
(Academic Press, NY, NY. 1976), the teachings of which are 
incorporated herein. TEMPO and several derivatives thereof 
can be purchased from Aldrich Chemical Co., as can many 
other spin traps such as PBN, DMPO, and POBN and some 
of their derivatives. 
DERIVATIVES OF TEMPO 
O O 
c c 
To cc];I c c N 
0 
As discussed above, the important criteria for these com 
pounds is that they must trap free radicals, especially 
hydroxy and superoxide radicals, while remaining non-toxic 
to normal cells. In those applications where the compound 
must reach the brain and other parts of the CNS, the 
compound must also be low molecular weight to pass‘ 
through the blood brain barrier. In some applications, the 
higher molecular weight dimers and polymers of the spin 
trap may have advantages. 
Conjugates and Polymers of Spin Trapping Compounds 
Examples of other useful compounds include conjugates 
of spin traps with known biologically active compounds, 
including drugs such as antiin?ammatories, neuroactive 
compounds, antioxidants, and calcium channel blockers. 
Examples include conjugates of acetaminophen, dopamine 
(or DOPA), vitamin E, and nifediphenyl: 
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-continued 
VITAMIN E AND ANALOGUES THEREOF 
14 
i‘ ‘F 
C=N + 
CH3 CH3 CH3 
0 l 
CH3 \ c—(CH3)3—CH—0 
1 
HO CH1 
CH2/ 
CH3 
H 
C3 ‘is ‘a ‘r? 0 
CH3 \ C-(cH3)3—CH—o C: + 
| 
H0 CH2 
CH3’ 
CH3 
CH3 
H 0 CH3 CH3 CH3 CH3 
| I | | | /0 CH3 
C=N—f“(CH2)3—CH—(CH2)s~CH—(CH2)3—$ 
CH3 CH1 OH 
\CH2 
CH3 
NIFEDIPHENYL PBN N03 
MeO ' COMe 
C 
II 
I|\I_ 
C—(|I— 
C 
Other drugs that can be conjugated to the spin traps gies, because the fundamental cause of the condition is 
include diltrazam, calcium channel blockers such as nicor- 45 oxidation of protein, nucleic acids, or lipids. 
dipine, nifedipine and nitrendipine, ?unarazine, digitalis Disorders are generally divided into disorders of ' the 
analogues, propranalol, desferal, and lazaroids. Conjugates central and peripheral nervous system and disorders of the 
with other types of biologically active molecules can also be peripheral organs. 
made, for example, with antibodies or ligands for speci?c Disorders of the CNS include stroke, aging, Parkin 
receptors (such as certain hormones, enzymes, or even 50 sonism, concussion, aneurysm, ventricular hemorrhage and 
speci?c sugars or carbohydrates) which are used to “target” associated vasospasm, migraine and other vascular head 
or otherwise concentrate the spin trapping compound. aches, spinal cord trauma, and neuroanesthesia adjunct. 
Depending on the structure of the spin trap, as well as the Disorders of the peripheral nervous system include diabetic 
biologically active compound, it may be necessary to insert peripheral neuropathy and traumatic nerve damage. 
a spacer between the spin trap and the biologically active 55 Peripheral organ disease includes atherosclerosis (both 
compound. diabetic and spontaneous), chronic obstructive pulmonary 
Indications that the compositions are useful in treating. disease (COPD), pancreatitis, pulmonary ?brosis due to 
The spin trap or free-radical scavenger compositions are chemotherapeutic agents, angioplasty, trauma, burns, 
useful in treating a variety of dysfunctions or disorders ischemic bowel disease, wounds, ulcers and bed sores, 
characterized by oxidized proteins or lipids in the tissues, 60 lupus, ulcerative colitis, organ transplantation, renal hyper 
cells, or associated ?uids (such as the blood). Oxidation of tertsion, overexertion of skeletal muscle, and epistaxis (pul 
cytosolic protein has been demonstrated to occur in a wide monary bleeding). 
variety of pathological conditions. Accordingly, compounds Other conditions associated: with excessive oxidation of 
which have as their fundamental mechanism of action the proteins or lipids that can be treated include undesirable or 
interference of production of oxidized protein should be 65 altered oxidation of low density lipoprotein, and dysfunction 
useful in the treatment of a wide variety of diseases having 
what appears at ?rst glance to be widely dissimilar etiolo 
from exposure to radiation, including x-ray, ultraviolet, 
gamma and beta radiation, and cytotoxic compounds, 
5,622,994 
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including those used for chemotherapy for cancer and viral 
infections. 
Treatment of Central Nervous System Diseases 
Stroke. 
Multiple in vitro studies, as well as the in vivo data 
presented in U.S. Ser. No. 07/589,177 (now abandoned) and 
U.S. Ser. No. 07/422,651 (U.S. Pat. No. 5,025,032) have 
demonstrated that there are a series of biochemical changes 
that result in the production of free radicals following 
ischernia. PBN and other spin-trapping compounds can 
covalently bind to these radicals and prevent the perioxida 
tion of cellular proteins and fatty acids. The consequence of 
the trapping of these carbon-centered and oxygen-centered 
radicals is the termination of the propagation phase of free 
radical production within the neuron. This interruption of 
free radical production can decrease the mortality and mor 
bidity seen in strokes. 
Aging 
Aging has been demonstrated to be associated with the 
production of abnormally high levels of oxidized proteins. 
The consequence of this increased level of protein oxidation 
is an abnormally low level of critical enzymes in the affected 
cells. While not all cells have been evaluated, it appears 
from the in vivo data presented in U.S. Ser. No. 07/589,177 
(now abandoned) and U.S. Ser. No. 07/422,65l, (U.S. Pat. 
No. 5,225,032) and reports of in vitro studies, that most, if 
not all, cells in the body will undergo abnormally high levels 
of protein oxidation. Decreases in antioxidant systems and 
abnormally low levels of mitochondrial function have been 
described. The protein oxidation is thought to arise from 
oxygen free radicals, largely generated via a metal catalyzed 
reaction within the cell. Studies have now been conducted 
that daily administration of a free radical spin trapping 
compound, PBN, for fourteen days completely reverses this 
process. Not only is the level of protein oxidation decreased, 
but the abnonnally low level of enzyme activity is restored 
to normal. - 
Parkinsonism 
Research has indicated that one of the principle sources of 
doparninergic damage to the striatum is via free radical 
mediated oxidation. Dopamine can be oxidized to the neu 
rotoxin 6-OH dopamine within the neuron. This neurotoxin 
is activated by a second oxidation. Both of these reactions 
are thought to occur as a result of oxygen free radical 
production and attack on the dopamine, a naturally occur 
ring neurotransmitter. These oxygen radical mediated oxi 
dations are thought to occur at a relatively slow rate and to 
be responsible ‘for the progressive loss of motor function in 
Parkinsonism and related conditions. Based upon the dem 
onstration that chronic administration of PBN can decrease 
the progressive oxidation that occurs following a stroke, it is 
believed that PBN and other spin-trapping compounds will 
be effective in limiting the production of the neurotoxic 
dopamine oxidation products. 
Concussion. 
The majority of the research literature indicates that 
concussion produces the bulk of its long term effects via 
interruption of brain and spinal cord microcirculation, pro 
ducing localized ischernia. This interruption in blood ?ow 
can be the result of the initial trauma and shearing of 
capillaries or the consequence of the brain edema and 
compression of the blood vessels. In any event, spin trapping 
compounds should be of therapeutic value as they have been 
demonstrated to be in models of stroke. 
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Berry Aneurysm and other types of Aneurysm. 
This vascular problem results in bleeding on the brain and 
presents as a serious and chronic headache or other neuro 
logic symptom. The condition is ultimately treated 'by sur 
gical repair of the vessel that has developed a weak wall. 
However, this condition oftert results in hemorrhage and 
neural damage due to the bleeding. In addition, the presence 
of blood on the outside of the vessel sensitizes the vessels to 
spasm and increases the risk of a stroke, as is also true in 
concussion and other traumatic conditions. In addition to the 
radicals generated by spasm and stroke, the iron or other 
metal catalyzed generation of oxygen free radicals, similar 
to what has been proposed for ischernia and concussion, also 
represents a second source of free radicals. 
Ventricular Hemorrhage and Associated Vasospasm. 
The same biochemical and physiological conditions as 
described for Berry Aneurysm and their management by 
spin trapping compounds will apply for these conditions. 
Migraine and other Vascular Headaches 
Migraines are thought to arise in part from vasodilation 
and compression of the microcirculation of the cortex. This 
is another form of ischemia/reperfusion injury. While spin 
trapping compounds will not prevent the initial occurrence 
of these vascular headaches, they should limit the extertt or 
frequency by trapping the free radicals that are generated 
during the ischernia phase. 
Spinal Cord Trauma. 
Spinal cord trauma involves the interruption of the normal 
vascular supply due to shearing forces at the time of the 
initial trauma and as a result of the subsequent edema of the 
tissue. In addition, the hemorrhage that oftert accompanies 
such trauma will also generate vasospasm and directly 
generated oxygen free radicals. Spin trapping compounds 
should limit this process and terminate the intracellular 
cascade of lipid and protein oxidation. 
Neuroanesthesia Adjunct. 
Several procedures involve resection of brain tissue which 
will result in hemorrhage in the immediate area. Other 
surgical procedures may be associated with increased riskof 
cerebral blood flow interruption, either as a natural conse 
quence of the procedure, e.g., cardiac surgery or heart 
transplantation, or due to the unexpected interruption of 
?ow, e.g., hemorrhage, clot following angioplasty, cardiac 
arrest during surgery. In all of these conditions, spin-trap 
ping compounds will limit free radical mediated damage. 
Peripheral Nervous System Diseases 
Diabetics are well known for their tertdencies to develop 
peripheral neuropathies and progressively loose sensation in 
limbs. In addition, diabetics have a higher risk to develop 
atherosclerosis, which may alfect microvascular function. 
One of the most frequently seen biochemical consequences 
of diabetes is excessive glycation of proteins. Following 
glycation, there is a burst of protein oxidation that is 
mediated by oxygen free radicals. It is though that this 
process of excessive glycation is critical in the development 
of damage to neurons and axons in the diabetic. Since spin 
trapping compounds are quite eifective in limiting intracel 
lular free radical mediated damage, such compounds should 
be useful in the chronic management of diabetic neuropa— 
thies and other long term adverse consequences of diabetes. 
Traumatic Nerve Damage. 
Crushing injury to peripheral nerves, as in the hands, 
arms, and legs, involves interruption of blood ?ow 
(ischemia) and edema. Effective and prompt repair is depen 
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dent on the re-establishment of an effective oxygen and 
nutrient supply. Oftert recovering tissue tertds to outgrow its 
blood supply and is restricted in recovery by the ischemia 
that occurs as the tissue outgrows the vascular supply. 
Spin-trapping compounds should provide greater tolerance 
of partial hypoxia as vascular supply grows to reach the 
healing tissue. In addition, the same ischemia/hypoxia pro 
tection that occurs in the non-vascular tissue may also 
enhance the growth of the endothelia as the revasculariza 
tion process occurs. 
Peripheral Organ Diseases 
Atherosclerosis (Both Diabetic and Spontaneous). 
Diabetic atherosclerosis involves the abnormal and exces~ 
sive glycation of protein in the vascular wall. As discussed 
above for diabetic neuropathy, this involves oxygen radical 
production and consequent further damage to cytosolic 
proteins. Spin-trapping compounds will prevent this abnor 
mal processing of cellular protein and other cellular con 
stituents. In vitro studies have been conducted that demon- ‘ 
strate that PBN inhibits or reduces oxidation of low density 
lipoprotein in plasma. Plasma samples were tested for oxi~ 
dation of lipid measured using thiobarbioturic acid reactive 
substance (TBAR, nM) and % inhibition of oxidation calcu 
lated. Phosphate bu?ered saline (PBS) was added to con 
trols, 0.1 mM PBN was added to test samples, and the 
controls and sealed samples incubated at 4° C. for seven 
weeks. 
The results are shown in Table I. 
TABLE 1 
Testing of antioxidation activity of PBN. 
sample control + PBS Test (nM/ml) % inhibition* 
NP132 plasma 0.55 0.45 18.2 
NP134 plasma 0.18 0.14 22.2 
NP135 plasma 0.32 0.25 21.9 
NP133 LDL 0.54 0.23 48.1 
NP135 LDL 0.33 0.11 66.7 
*The actual percent inhibition in the presence of PBN is greater than the 
measured value due to interference in the assay by the PBN. 
Chronic Obstructive Pulmonary Disease (COPD). 
COPD has been demonstrated to involve the attack of 
interstitial alveolar macrophages on pulmonary tissue. Ani 
mals models of this clinical condition have demonstrated 
that increases or decreases in superoxide dismutase activity 
in the lung can result in decreases or increases in pulmonary 
pathology, respectively. An alternative approach is to pro 
vide to the pulmonary tissue, either via the pulmonary 
vascular supply or via the airway, radical spin-trapping 
compounds which will limit the peroxidation of pulmonary 
tissue and the consequent loss of alveolar tissue. 
Pancreatitis. 
Pancreatitis is believed to be the result of ischernic or 
chemically derived peroxidation of pancreatic parenchyma. 
Alcoholic pancreatitis is probably due to the direct effects of 
the ethanol radical and the indirect vascular effects of 
acetaldehyde mediated direct damage to proteins and indi 
rect damage via catecholamine release and mitochondrial 
metabolism. There is currently no treatment for acute pan 
creatitis. If the condition does not abate, it is generally 
regarded as fatal in the severe form. Spin -trapping agents 
may mediate the acute reaction, allowing the patient time to 
recover. 
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Angioplasty. 
In the process of re~expanding or laser removal of 
atheroma, there are periods of ischemia and reperfusion of 
the vessel. Recent studies have demonstrated that during this 
period, superoxide and nitric oxide are produced. These 
products have been demonstrated to further damage the 
endothelium and may also remove or damage the natural. 
relaxant systems that locally control the vascular tone. If 
uncontrolled, such changes are likely to result in an 
increased risk of re-occlusion of the same vessel. Spin 
trapping compounds can prevent the generation of the 
oXy-radical cascade and thereby reduce the likelihood of 
reocclusion following angioplasty. 
Multi-organ Failure Following Trauma. 
A characteristic problem following extreme trauma is the 
development in the patient of a negative nitrogen balance, 
poor protein synthetic capacity, pulmonary dysfunction, and 
abnormal cytokine production. Tumor necrosis factor (TNF) 
is excessively elevated during this process. TNF is associ 
ated with the cellular generation of oxygen free radicals in 
tissue and may be one of the primary causes of this condi 
tion. The activation of macrophages and lymphocytes also 
plays a critical role in the condition- Free radical production 
by the white cells is part of the process of multiple organ 
‘damage. Spin-trapping compounds can prevent the propa 
gation phase of this condition and limit the extent of 
cachexia and organ damage following severe trauma. 
Diabetic Retinopathy. 
Diabetes is a disease of abnormal glycation and partial 
ischemia. Both conditions promote free radical production. 
The relatively common condition of diabetic retinopathy is 
thought to involve a microvascular and protein dysfunction 
of the retina. Spin-trapping compounds can limit the glyca 
tion mediated production of free radicals and the~damage 
caused by rnicrovascular interruptions. 
Burn Treatment and Healing. 
Healing from serious bums is limited by the inability of 
the repairing vascular system to supply the rapidly growing 
cutaneum. Periods of ischemia in the dermis will occur as 
the growing skin cannot be adequately supplied. This 
hypoxia or ischemia results in the production of oxygen free 
radicals and either limits the rate of recovery and/or pro~ 
motes the generation of scar tissue. Systemic and topical 
spin-trapping compounds should improve the rate of healing 
and decrease scar formation. 
Ischernic Bowel Disease 
strangulation of the bowel is a condition that is frequently 
fatal in both humans and animals such as dogs, horses and 
cattle. Even after resection and anastomosis of the intestine, 
the prognosis is not good. The generation of ischemia 
derived oxygen radicals and damage to the intestine is 
considered to the be primary cause. There is no effective 
treatment to date. 
Studies have demonstrated that ischemia induced intesti 
nal edema can be prevented or reduced by a number of 
different spin-trapping compounds. 
Endotoxin is a primary factor in the pathophysiology of 
equine gastrointestinal disorders and gram negative bacterial 
infections. The pathophysiological is similar to that charac 
terizing colitis, salmonellosis, and neonatal septicemia. It is 
hypothesized that endotoxin produces its toxic effects by 
triggering “oxidative bursts” from sensitized macrophages. 
These bursts of OZ radicals are intertded to kill invading 
bacteria associated with the presence of endotoxin. How 
ever, they have the adverse eifect of damaging the tissues in 
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which they are produced and this tissue damage is presum 
ably the molecular basis of the pathological changes asso 
ciated with endotoxin shock. Spin-trapping compounds have 
the ability to trap radicals and alleviate many of the toxic 
effects associated with radical formation. Additionally, 
recent experiments demonstrate that spin trap molecules 
protect rats against endotoxin administration. 
Wound and Ulcer Healing. 
Tissue healing oftert involves periods of hypoxia or 
ischemia as the recovering tissue outgrows the vascular 
supply. Spin-trapping compounds can decrease the damage 
associated with this period of ischemia. 
Infections as consequence of the development of decubi 
tus ulcers is the number one cause of death in the elderly. 
The general clinical impression is that elderly patients are 
much more likely to develop these ulcers, compared to 
young adults. Pressure sores develop as a result of the 
interruption of blood ?ow to the skin. This process is 
identical to the process of ischemia/reperfusion oxidation of 
brain and other tissues. In the geriatric patient, pressure 
sores may rapidly develop due to the enhanced oxidation of 
cells in the skin. Based upon the observations that spin 
trapping compounds can prevent ischemia/reperfusion 
injury to both brain and intestine, it is expected that spin 
trapping compounds will reduce or prevent pressure sores. 
In addition, these compounds should be useful systemically 
or topically in enhancing recovery. 
Reduction in Side-effects of Cancer Chemotherapy. 
A number of cancer chemotherapeutic agents produce 
their cytotoxic effects via the production of oxygen free 
radicals within the cell. The limiting side effects of these, 
compounds are also the result of oxygen free radical pro 
duct'ion in normal cells. Bleomycin produces pulmonary and 
cutaneous toxicities as a result of hydroxyl free radical 
production. Adriamycin produces cardiac and gastrointesti' 
nal side~effects. The spin-trapping compound PBN has been 
demonstrated to trap the free radicals produced by adriamy 
cin in heart, brain and other organs of research animals, 
using the spin-trapping compound PBN. These spin-trap 
ping compounds should be useful in limiting side effects in 
tissues, such as the brain, that the especially vulnerable to 
develop free radicals without compromising the therapeutic 
value of the chemotherapeutic‘agent. 
Skin, Muscle Flap and Organ Survival Following Trans 
plantation. 
Autologous (self) transplantation of skeletal muscles from 
area to the other should not involve any immunologic 
incompatibilities. However, estimates from surgeons sug 
gest that the success rate is more in the area of 50% success. 
Acceptance of skin ?ap grafts has an equally low success 
rate. It is postulated much of the problem arises a result of 
ischemia and reperfusion during the surgical procedures for 
removal and implantation. Following ischemia these tissues 
undergo calcium loading and eventually necrosis, as in 
strokes. Spin-trapping compounds should therefore be 
equally effective in limiting the damage undergone by these 
tissues, as well as other organs, during surgery associated 
with transplantation. 
Organs for transplantation are obtained from donors. The 
success of the procedure is determined in part by the age 
(oxidation) related reduction in organ viability, the amount 
of time the organ is in preservation solution and the status of 
the recipient. Previous research has demonstrated that spin 
trapping compounds can improve the enzymatic status of the 
aged brain, restoring enzymatic levels to near those of the 
young adult as early as seven days following initiation of 
daily treatment with a spin-trapping agent such as PBN. 
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Organ preservation solutions are designed to prepare ‘the 
organ to be transplanted for the period of extracorporeal 
storage. The most recently developed solution contains 
glutathione as an antioxidant. Spin-trapping compounds 
differ from glutathione in that they can function both as 
antioxidants, trapping oxygen free radicals, as well as trap 
ping compounds for both intracellular and extracellular 
carbon-centered free radicals. 
It is believed organ survival would therefore be enhanced 
by administering spin-trapping compounds to the recipient, 
as well as adding the compounds to the organ preservation 
solution. 
Ionizing Radiation Prophylaxis. 
Ionizing radiation as a therapeutic modality and as an 
environmental toxicant causes its effects by producing 
hydroxyl free radicals intracellularly and extracellularly. 
Ultraviolet radiation acts similarly. The cascade that follows 
is functionally identical to the process of cellular damage 
caused by ischemia/reperfusion injury to tissue. By selec 
tively treating with spin-trapping compounds those tissues 
that are not involved by the cancer, it should be possible to 
improve the effectiveness and decrease the side effects of 
radiation therapies. In the case of environmental exposures, 
spin-trapping compounds‘ should be effective both as ea 
prophylaxis, applied topically or systemically, as well as a 
post-exposure therapeutic. , 
Treatment of Renal Hypertertsion Disorders, resulting 
from low renal artery ?ow and high renin. 
Renal hypertertsion develops as a result of reduced blood 
?ow to the kidney. The juxtaglomerular apparatus (JGA) 
recognizes this hypoperfusion and releases renin, which 
results in an angiotertsin H mediated increase in blood 
pressure (hypertertsion). Hypoperfusion (hypoxia) is a con 
dition that is known to result in signi?cant oxygen free 
radical production, making it probable that oxygen free 
radicals are likely to be involved in the release of renin by 
the JGA, and therefore manageable at least in part through 
administration of spin-trapping compounds. 
Exertional Injury to skeletal muscle. 
Sore muscles as a result of exercise are thought to be a 
consequence of free radical mediated perioxidation of skel 
etal muscle proteins and lipids. Since chronic treatment with 
spin-trapping compounds decreases cellular oxidations and 
protects enzymes from oxidative inactivation, daily treat 
ment should improve the process of exercise conditioning 
(especially in the horse). Moreover, aged skeletal muscle is 
likely to contain constituents, as do most other cells in the 
body. Previous work has demonstrated that chronic admin 
istration of the spin-trapping compound PBN can return 
cells to the status of a young adult, spin-trapping compounds 
should be effective in improving the functional status and 
exercise condition of skeletal muscle in aged individuals. 
Epistaxis (Pulmonary Bleeding in Horses) and Laminitis 
Epistaxis (ES) and laminitis are both thought to involve 
ischemia/reperfusion injury to the alveolar basement mem' 
brane and the lamina propria of the hoof, respectively. Since 
both of these conditions involve the process of reperfusion 
generation of free radicals, spin-trapping compounds should 
be e?ective in the prevention, management of treatment of 
these conditions. 
Pharmaceutical Compositions 
The spin trapping compounds are administered topically, 
locally, or systemically, depending on the application. When 
administered systemically, the compound is preferably 
administered orally or intravenously, in an appropriate phar 
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maceutical carrier such as saline or phosphate buffered 
saline (PBS) or in tablet form. For topical application, the 
compound is preferably administered in an ointment or 
cream base, or by means of a transdermal patch. The 
compound can also be administered by controlled delivery 
devices, such as biodegradable polymers, or by inhalation, 
insu?lation or nasal spray. Suitable carriers are known to 
those skilled in the pharmaceutical area. 
Effective dosages of Spin Trapping Compounds 
Exemplary dosages of PBN administered intravenously 
range from 0.1 to 10 mg/kg of body weight in animals. The 
effective dosage of PBN in humans for treating age and 
ischemic related disorders is expected to be between 
approximately 1 and 10 mg/70 kg body weight. Toxicity 
tests have demonstrated that the compound is completely 
innocuous, with such low toxicity that it was not possible to 
determine an LDSQ. It is possible to extrapolate from com 
- parative tests using other spin trapping compounds what the 
elfective dosage for these compounds will be. 
Since the trapping of endogenous free radicals is speci?c 
for only those cells that have been exposed to the conditions 
that result in the production of free radicals, the traps have 
little or no effect on normal cells. The bene?cial effects 
occur only in injured cells, and do not require the presence 
of speci?c receptors, speci?c enzymes, and/or speci?c cell 
types. 
Methods of administration of PBN. 
The spin trapping compound is preferably administered 
systemically, most preferably intravenously or orally, since 
these are the most rapid and ef?cient means for delivering 
the active compound to the site of free radical generation. 
The spin trapping compound may be administered at once, 
or may be divided into a number of smaller doses to be 
administered at varying intervals of time. Other methods of 
systemic administration can also be used, including inhala 
tion or insu?lation, subcutaneous, intravenous, and intrap 
eritoneal administration. The spin trapping compound can 
also be administered topically, in an ointment, creme, or 
transdermal patch. The concentration of active compound in 
the drug composition will depend on absorption, inactiva 
tion, and excretion rates of the drug as well as other factors 
known to those skilled in the art. It is to be noted that dosage 
values will also vary with the condition of the patient being 
treated. It is to be further understood that for any particular 
subject, speci?c dosage regimens should be adjusted over 
time according to the individual need and the professional 
judgment of the person administering or supervising the 
administration of the compositions, and that the concentra 
tion ranges set forth herein are exemplary only and are not 
intertded to limit the scope or practice of the claimed 
composition. 
A preferred mode of administration of the active com» 
pound is in a form for oral delivery. Oral compositions will 
generally include an inert diluent or an edible carrier. 
Preferred pharmaceutical carriers for intravenous adminis 
tration are saline or phosphate bu?ered saline at physiologi 
cal pH. Since some compounds are pH sensitive, stability of 
the compound in the carrier should be determined and the 
pH of the carrier adjusted appropriately, or the compound 
administered in combination with food, a buffering agent, or 
in an enteric coating. For oral delivery, the spin trapping 
compound may be enclosed in capsules, compressed into 
tablets, nricroencapsulated, entrapped in liposomes, in solu 
tion or suspension,alone or in combination with a substrate 
immobilizing material such as starch or poorly absorbable 
salts such as immodium. Phannaceutically compatible bind 
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ing agents can be included as part of the composition. The 
tablets or capsules may contain, for example, any of the 
following ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disintegrat 
ing agent such as alginic acid, Primogel®, or corn starch; a 
lubricant such as magnesium stearate or Sterotes; a glidant 
such as colloidal silicon dioxide; a sweeterting agent such as 
sucrose or saccharin; or a ?avoring agent such as pepper 
mint, methyl salicylate, or orange ?avoring. When the 
dosage unit form is a capsule, it can contain, in addition to 
material of the above type, a liquid. carrier. In addition, 
dosage unit forms can contain various other materials which 
modify the physical form of the dosage unit, for example, 
coatings of sugar, shellac, or other enteric agents. 
Modi?cations and variations of the spin trapping compo 
sitions for the treatment of a variety of disorders associated 
with oxidation of proteins and/or lipids will be obvious to 
those skilled in the art from the foregoing detailed descrip 
tion. Such modi?cations and variations are intertded to come 
within the scope of the appended claims. 
We claim: 
1. A method for ameliorating the side e?cects caused in a 
patient by oxidative damage resulting from the administra 
tion to said patient of a cancer therapeutic agent, said 
method comprising administering to said patient an effective 
side effect-ameliorating amount of an active ingredient 
selected from the group consisting of: 
(l) phenyl N-tert-butyl nitrone (PBN) derivatives selected 
from the group consisting of hydroxy PBNs, PBN 
esters, acetoxy PBNs, phenyl PBNs, alkyl PBNs, 
alkoxy PBNs, acetamide PBNs, and diphenyl PBNs; 
(2) imidazole PBN, phenothiazinyl PBN, nitrosobenzene 
PBN, 2-methyl nitrosopropane PBN, PBN Cyclodext 
ran polymer and cyclized PBN; 
(3) 5,5-dimethyl pyrroline N-oxide (DMPO) esters, 
acetoxy DMPOs, phenyl DMPOs, alkyl DMPOs, aceta 
mide DMPOs, diphenyl DMPOs, and DMPO dimers; 
(4) alpha-(4-pyridyl 1-oxide)~N-tert-butylnitrone (POBN) 
esters, hydroxy POBNs, phenyl POBNs, alkoxy 
POBNs, and acetamide POBNs; 
(5) N-tert-butyl-alpha-(4-nitro-phenyl)nitrone; 
(6) N-tert-butyl-alpha-(2-sulfophenyl)nitrone; 
(7) 3,3,5,5-tetramethyl-1-pyrroline N-oxide; 
(8) 2,4,o-tri-tert-butylnitrosobenzene (BNB); and 
(9) 2,2,6,6-tetrarnethyl piperidinooxy (TEMPO), 
optionally in association with a pharrnaceutically accept 
able carrier. 
2. The method of claim 1 wherein said cancer therapeutic 
agent is selected from the group consisting of bleomycin and 
adriamycin. 
3. The method of claim 1 wherein said active ingredient 
is a PBN derivative selected from the group consisting of 
hydroxy PBNs, PBN esters, acetoxy PBNs, phenyl PBNs, 
alkyl PBNs, alkoxy PBNs, acetamide PBNs, and diphenyl 
PBNs. 
4. The method of claim 1 wherein said active ingredient 
is a PBN derivative selected from the group consisting of 
imidazole PBN, phenothiazinyl PBN, nitrosobenzene PBN 
and 2-methyl nitrosopropane PBN. 
5. The method of claim 1 wherein said active ingredient 
is selected from the group consisting of DMPO derivatives 
selected from the group consisting of DMPO esters, acetoxy 
DMPOs, phenyl DMPOs, alkyl DMPOs, acetamide 
DMPOs, diphenyl DMPOs, and DMPO dimers. 
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6. The method of claim 1 wherein said active ingredient 
is selected from the group consisting of POBN derivatives 
selected from the group consisting of POBN esters, hydroxy 
POBNs, phenyl POBNs, alkoxy POBNs, and acetamide 
POBNs. 
7. The method of claim 1 wherein said active ingredient 
is administered in association with a pharrnaceutically 
acceptable carrier. 
8. A method for ameliorating the side e?ects caused in a 
patient by oxidative damage resulting from the administra 
tion to said patient of a cancer therapeutic agent, said 
method comprising administering to said patient an eifective 
side-e?ect ameliorating amount of an active ingredient 
de?ned by the formula: 
H 0 (I) 
/ 
X Y 
wherein: 
X is phenyl or 
(0K)» 
wherein R is H, 
O O 
and n is a whole integer from l to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
0 0 
II II II 
c-cm, NH-C-Z, c—oz, 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group, 
excluding compounds of formula (I) wherein Y is a 
tert-butyl group when X is phenyl, optionally in asso~ 
ciation with a pharrnaceutically acceptable carrier. 
9. The method of claim 8 wherein X is 
10. The method of claim 8 wherein Z is methyl. 
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11. The method of claim 8 wherein X is 
(ORH) 
12. The method of claim 8 wherein Y is a tert~butyl group. 
13. The method of claim 9 wherein Y is a tert-butyl group. 
14. The method of claim 8 wherein Y is phenyl. 
15. The method of claim 8 wherein Y is 
OW 
16. The method of claim 8 wherein Z is C1 to C5 straight 
chain alkyl. 
17. The method of claim 8 wherein said active ingredient 
is administered in association with a pharrnaceutically 
acceptable canier. 
18. A method for ameliorating the side eifects caused in 
a patient by oxidative damage resulting from the adminis 
tration to said patient of a cancer therapeutic agent, said 
method comprising administering to said patient an effective 
side e?°ect-ameliorating amount of an active ingredient 
de?ned by the formula: 
wherein A and B are independently CH2OH, CHZOW, or 
s 
n is an integer from 1 to 5, 
wherein W is 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group, optionally 
in association with a pharmaceutically acceptable car 
rier. 
19. The method of claim 18 wherein A and B are inde-, 
pendently selected from the group consisting of CHZOH and 
CHZOW. 
20. The method of claim 18 wherein at least one of A and 
B is 
21. The method of claim 18 wherein said active ingredient 
is administered in association with a pharrnaceutically 
acceptable carrier. 
22. A method for ameliorating the side e?’ects caused in 
a patient by oxidative damage resulting from the adminis 
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tration to said patient of a cancer therapeutic agent, said 
method comprising administering to said patient an eifective 
side effect-ameliorating amount of an active ingredient 
de?ned by the formula: 
i 
wherein 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
1 
wherein W is 
O O 0 
II II II 
NH—-C—Z, —C——CH3, -—C—OZ, 
or Z; and 
S is (0K)", wherein R is H, 
i’ °‘ 
Z—C—, Z, or —Cl-l=N+ 
Y 
n is a whole number from 1 to 4, or 
and 
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Z is a C1 to C5 straight or branched alkyl group, optionally 
in association with a pharmaceutically acceptable car 
r1er. 
23. The method of claim 22 wherein Y is a tert-butyl 
group. 
24. The method of claim 22 wherein Y is phenyl. 
25. The method of claim 22 wherein Y is 
OW 
26. The method of claim 22 wherein S is OH. 
27. The method of claim 22 wherein Z is a C1 to C5 
straight alkyl group. 
28. The method of claim 22 wherein S is 
29. The method of claim 22 wherein S is 
30. The method of claim 22 wherein S is a C1 to C5 
straight or branched alkyl group. 
31. The method of claim 22 wherein said active ingredient 
is administered in association with a pharmaceutically 
acceptable cairier. 
32. The method of claim 1 wherein the active ingredient 
is N-tert-butyl-alpha-(4-nitrogphenyl) nitrone. 
33. The method of claim 1 wherein the active ingredient 
is N~tert-butyl-a1pha-(2-sulfophenyl) nitrone. 
34. The method of claim 1 wherein the active ingredient 
is 3,3,5,5-tetramethyl-l-pyrroline N-oxide. 
35. The method of claim 1 wherein the active ingredient 
is 2,4,6-t1i-tert-butylnitrosobenzene. . 
36. The method of claim 1 wherein the active ingredient 
is 2,2,6,6-tetramethyl piperidinooxy. 
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